Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.

Tai, Ting-An; Latimer, Nicholas R; Benedict, Ágnes; Kiss, Zsofia; Nikolaou, Andreas

Tai, Ting-An; Latimer, Nicholas R; Benedict, Ágnes; Kiss, Zsofia; Nikolaou, Andreas.

Tai TA; School of Health and Related Research, University of Sheffield, Sheffield, England, UK. Electronic address: tinantai@gmail.com.
Latimer NR; School of Health and Related Research, University of Sheffield, Sheffield, England, UK.
Benedict Á; Modelling and Simulation, Evidera, Budapest, Hungary.
Kiss Z; Modelling and Simulation, Evidera, London, England, UK.
Nikolaou A; Modelling and Simulation, Evidera, London, England, UK.

Value Health ; 24(4): 505-512, 2021 04.

Article en En | MEDLINE | ID: mdl-33840428

Asunto(s)

Antineoplásicos/economía; Antineoplásicos/uso terapéutico; Toma de Decisiones; Neoplasias; Evaluación de la Tecnología Biomédica/métodos; Análisis Costo-Beneficio; Gobierno Federal; Humanos; Reembolso de Seguro de Salud/economía; Modelos Económicos; Neoplasias/tratamiento farmacológico; Neoplasias/economía; Neoplasias/mortalidad; Prevalencia; Análisis de Supervivencia; Estados Unidos/epidemiología

Palabras clave

cost-utility analysis; health technology assessment; immature survival data; oncology; survival analysis; survival extrapolation

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Evaluación de la Tecnología Biomédica / Toma de Decisiones / Neoplasias / Antineoplásicos Tipo de estudio: Guideline / Health_economic_evaluation / Health_technology_assessment / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País como asunto: America do norte Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google